Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 43%
Hold 14%
Sell 7%
Strong Sell 0%

Bulls say

Alkermes is a fully integrated biotechnology company, utilizing various technologies to develop and commercialize pharmaceutical products, with strong focus on unmet medical needs. Their recent LTE study in NT1 and NT2 showed sustained efficacy and improvements in safety and potential future indications, supporting their currently undervalued stock price. The company has a strong pipeline, including ALKS 4510 and ALKS 7290, with potential updates later this year that could further boost their strong financial performance.

Bears say

Alkermes is at a disadvantage with their limited sales force for their only currently marketed product, and although their recent LTE data for an OX2R agonist looks promising, it has only been tested in a heterogenous population and still needs to undergo pivotal studies. Additionally, their management will need to dedicate more resources towards marketing and expanding their sales force in preparation for the launch of alixorexton and targeting both REMS certified and uncertified physicians.

Alkermes (ALKS) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 14 analysts, Alkermes (ALKS) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.